Hidradenitis Suppurativa: Clinical Trials

90 trials for Hidradenitis Suppurativa, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

49 completed, 15 recruiting, 10 terminated, 8 active not recruiting. 90 Phase 2, 6 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 290Completed 49, Recruiting 15, Terminated 10, Active not recruiting 8, Unknown 4, Not yet recruiting 2, Withdrawn 2
Phase 16Completed 3, Recruiting 2, Unknown 1
Phase 33Active not recruiting 1, Completed 1, Terminated 1

Follow Hidradenitis Suppurativa: new trials by email Literature Review of Hidradenitis Suppurativa trials Research Report on Hidradenitis Suppurativa

Trials (filtered) newest first · largest first

All 90 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of SL-325 in Participants With Hidradenitis Suppurativa
SL-325, Placebo - Hidradenitis Suppurativa (HS)
Phase 2Not yet recruitingShattuck Labs, Inc.1502027-01-012026-11-13
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Olatorepatide, Placebo - Hidradenitis Suppurativa
Phase 2RecruitingRegeneron Pharmaceuticals3002026-10-292026-11-10
A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
SPY072, Placebo, bimekizumab - Hidradenitis Suppurativa (HS)
Phase 2RecruitingSpyre Therapeutics, Inc.1502026-10-062026-11-18
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS)
Phase 2Not yet recruitingUniversity of Massachusetts, Worcester402026-10-012026-09-10
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS)
Phase 2RecruitingHarrison Dermatology102026-09-102026-10-13
The Safety and Efficacy of Roflumilast Foam in HS
Roflumilast 0.3% topical foam - Hidradenitis Suppurativa (HS)
Phase 2RecruitingBeth Israel Deaconess Medical Center202026-09-012026-07-09
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
ORKA-002, Placebo - Hidradenitis Suppurativa (HS)
Phase 2RecruitingOruka Therapeutics, Inc.2002026-08-212026-10-29
A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa
Upadacitinib - Hidradenitis Suppurativa (Acne Inversa)
Phase 2Active not recruitingPeking Union Medical College502026-07-012026-07-27
A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa
LAD328, Placebo - Hidradenitis Suppurativa
Phase 2RecruitingAlmirall, S.A.502026-05-132026-08-17
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Povorcitinib - Hidradenitis Suppurativa (HS)
Phase 2RecruitingIncyte Corporation402026-02-022026-11-13
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Zasocitinib (Dose A), Placebo - Hidradenitis Suppurativa
Phase 2Active not recruitingTakeda912026-01-262026-11-04
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NAV-240, Placebo to match NAV-240 - Hidradenitis Suppurativa (HS)
Phase 2RecruitingNavigator Medicines, Inc.1502026-01-052026-07-22
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
SAR445399, Placebo - Hidradenitis Suppurativa
Phase 2RecruitingSanofi1442025-12-292026-10-16
Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa
SCT650C - Hidradenitis Suppurativa (HS)
Phase 2RecruitingSinocelltech Ltd.602025-12-162026-04-28
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
Ritlecitinib, Placebo - Hidradenitis Suppurativa
Phase 2Active not recruitingPfizer1282025-11-132026-11-10
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Brivekimig, Placebo - Hidradenitis Suppurativa
Phase 2RecruitingSanofi2082025-11-062026-10-14
A Study of LAD191 in Adults With Hidradenitis Suppurativa
LAD191, Placebo, Adalimumab - Hidradenitis Suppurativa
Phase 2RecruitingAlmirall, S.A.2002025-11-052026-05-11
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
BFB759, Placebo for BFB759 - Hidradenitis Suppurativa (HS)
Phase 2 / Phase 3Active not recruitingBluefin Biomedicine, Inc.2102025-11-032026-10-14
A Study With CIT-013 in HS Patients
CIT-013 high dose, CIT-013 medium dose, Placebo - Hidradenitis Suppurativa (HS)
Phase 2Active not recruitingCitryll BV1082025-10-312026-10-19
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
Topical roflumilast 0.3% foam - Hidradenitis Suppurativa
Phase 2CompletedTulane University102025-09-252026-10-09

Showing 20 of 90. Sign in to see all of them.

Narrower conditions

Hidradenitis (9)  ·  Skin Diseases (9)  ·  Abscess (3)  ·  Sweat Gland Diseases (3)  ·  Dermatitis (2)  ·  Dermatitis, Atopic (2)  ·  Inflammation (2)  ·  Skin Diseases, Bacterial (2)  ·  Acne Vulgaris (1)  ·  Alopecia Areata (1)  ·  Autoimmune Diseases (1)  ·  Chronic Urticaria (1)  ·  Down Syndrome (1)  ·  Eczema (1)

Broader conditions

Bacterial Infections (90)  ·  Bacterial Infections and Mycoses (90)  ·  Skin Diseases, Infectious (90)  ·  Infections (89)  ·  Skin and Connective Tissue Diseases (89)  ·  Suppuration (89)  ·  Skin Diseases, Bacterial (88)  ·  Sweat Gland Diseases (87)  ·  Hidradenitis (81)  ·  Skin Diseases (81)  ·  Pathologic Processes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Inflammation (4)  ·  Hypersensitivity (3)  ·  Hypersensitivity, Immediate (3)

Interventions

Adalimumab (6)  ·  Roflumilast (3)  ·  Sodium Chloride (3)  ·  BDB001 (2)  ·  Gentian Violet (2)  ·  Injections (2)  ·  Interleukin 1 Receptor Antagonist Protein (2)  ·  apremilast (2)  ·  bermekimab (2)  ·  bimekizumab (2)  ·  guselkumab (2)  ·  lutikizumab (2)  ·  spesolimab (2)  ·  upadacitinib (2)  ·  vilobelimab (2)

Sponsors

Incyte Corporation (5)  ·  AbbVie (4)  ·  Boehringer Ingelheim (4)  ·  Florida Academic Dermatology Centers (4)  ·  Janssen Research & Development, LLC (4)  ·  Sanofi (4)  ·  Beth Israel Deaconess Medical Center (3)  ·  InflaRx GmbH (3)  ·  Almirall, S.A. (2)  ·  Eli Lilly and Company (2)  ·  Novartis Pharmaceuticals (2)  ·  Pfizer (2)  ·  Staidson (Beijing) Biopharmaceuticals Co., Ltd (2)  ·  University Medical Center Groningen (2)  ·  University of Athens (2)

Countries

United States (65)  ·  Canada (35)  ·  Germany (32)  ·  Poland (24)  ·  Spain (23)  ·  Netherlands (20)  ·  Australia (19)  ·  France (16)  ·  Greece (16)  ·  China (10)  ·  Bulgaria (9)  ·  Denmark (9)  ·  Japan (9)  ·  Czechia (8)  ·  Italy (8)

Top investigators

Baoxi Wang, Master (2)  ·  Evangelos J Giamarellos-Bourboulis, MD, PhD (2)  ·  Francisco A Kerdel, M.D (2)  ·  Kathleen Butler, MD (2)  ·  Martina Porter, MD (2)  ·  Ajay Aggarwal (1)  ·  Alexandra B Kimball, MD, MPH (1)  ·  Alexandra Kimball, MD, MPH (1)

Results publications

PMID 34252397, PMID 34978076, PMID 19185954, PMID 20115947, PMID 23247938, PMID 26579854, PMID 27136622, PMID 29380251, PMID 32004568, PMID 34406364, PMID 36892753, PMID 37317022, PMID 37522746, PMID 38335032, PMID 38946973, PMID 39737640, PMID 39899371, PMID 39909350, PMID 41061970, PMID 41081529, PMID 41848710

NIH funding

2025 (7), 2023 (3), 2018 (2), 2004 (1), 2008 (1), 2017 (1), 2019 (1), R33AR077495 (1), R61AR087105 (1)